Prostamax dosage

Prostamax oral dosage

A transferable human dose and treatment schedule for Prostamax by this route have not been established.[8][1]

Prostamax is the Lys-Glu-Asp-Pro tetrapeptide associated with prostate-cell signaling. Capsule, drop, injectable and suppository preparations differ in concentration and reproducibility.[8][9][2][3]

Prostamax subcutaneous dosage

A reported subcutaneous pattern lists 1–5 mg daily for ten days, followed by an unspecified break measured in months. This does not resolve the product-strength and preparation uncertainties in the injection patents or establish an equivalent capsule or suppository dose.[4][10]

Prostamax is the Lys-Glu-Asp-Pro tetrapeptide associated with prostate-cell signaling. Capsule, drop, injectable and suppository preparations differ in concentration and reproducibility. The intramuscular patent examples do not establish an equivalent dose or a reproducible current-product preparation.[4][2][3]

Prostamax rectal — patent formulation dosage

The patent composition specifies 0.0003–0.0010 g of Lys-Glu-Asp-Pro in each 1 g suppository, equivalent to 0.3–1 mg. Its clinical example instead prints the same numerical range in milligrams, a 1,000-fold unit conflict. The composition can be described, but a clinical dose and schedule cannot be selected from these inconsistent strengths.[1]

Prostamax is the Lys-Glu-Asp-Pro tetrapeptide associated with prostate-cell signaling. Capsule, drop, injectable and suppository preparations differ in concentration and reproducibility.[1][2][3]

Frequency and timing

A reproducible clock-time or meal-timing anchor is not established across the oral and patent preparations.[8][4]

Cycle length and breaks

Subcutaneous: 10 days. A standard break interval between courses is not established.[10]

Approval and product quality

Prostamax is not an FDA-approved drug.[7]

Side effects and long-term safety

Human side-effect rates, interactions and long-term safety are not established for a characterized preparation. Conflicting strengths and incomplete preparation information prevent a dependable cross-product dose.[4][2][5][6][1]

Route-specific dosing limits

Controlled human safety data are lacking. Unresolved dose-unit conflicts in the rat reports and suppository patent make dose comparisons particularly unreliable. Additional schedules attributed to Everything Peptide are reported patterns; citing research does not make these schedules clinically established or approved product instructions.[5][6][1][10]